Deng Min, Li Shao-Hua, Fu Xu, Yan Xiao-Peng, Chen Jun, Qiu Yu-Dong, Guo Rong-Ping
Department of Liver Surgery, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, China.
State Key Laboratory of Oncology in South China, Guangzhou, China.
Cancer Cell Int. 2021 Jul 12;21(1):371. doi: 10.1186/s12935-021-02081-w.
Programmed death- ligand 1 (PD-L1) seems to be associated with the immune escape of tumors, and immunotherapy may be a favorable treatment for PD-L1-positive patients. We evaluated intrahepatic cholangiocarcinoma (ICC) specimens for their expression of PD-L1, infiltration of CD8+ T cells, and the relationship between these factors and patient survival.
In total, 69 resections of ICC were stained by immunohistochemistry for PD-L1, programmed death factor-1 (PD-1), and CD8+ T cells. CD8+ T-cell densities were analyzed both within tumors and at the tumor-stromal interface. Patient survival was predicted based on the PD-L1 status and CD8+ T-cell density.
The expression rate of PD-L1 was 12% in cancer cells and 51% in interstitial cells. The expression rate of PD-1 was 30%, and the number of CD8+ T-cells increased with the increase of PD-L1 expression (p < 0.05). The expression of PD-L1 in the tumor was correlated with poor overall survival(OS) (p = 0.004), and the number of tumor and interstitial CD8+ T-cells was correlated with poor OS and disease-free survival (DFS) (All p < 0.001).
The expression of PD-L1 in the tumor is related to poor OS, and the number of tumor or interstitial CD8+ T-cells is related to poor OS and DFS. For patients who lose their chance of surgery, PD-L1 immunosuppressive therapy may be the focus of future research as a potential treatment.
程序性死亡配体1(PD-L1)似乎与肿瘤的免疫逃逸有关,免疫治疗可能是PD-L1阳性患者的一种有效治疗方法。我们评估了肝内胆管癌(ICC)标本中PD-L1的表达、CD8+T细胞的浸润情况,以及这些因素与患者生存率之间的关系。
总共对69例ICC切除标本进行免疫组织化学染色,检测PD-L1、程序性死亡因子-1(PD-1)和CD8+T细胞。分析肿瘤内部和肿瘤-基质界面处的CD8+T细胞密度。根据PD-L1状态和CD8+T细胞密度预测患者生存率。
癌细胞中PD-L1的表达率为12%,间质细胞中为51%。PD-1的表达率为30%,CD8+T细胞数量随PD-L1表达增加而增加(p<0.05)。肿瘤中PD-L1的表达与总生存期(OS)较差相关(p=0.004),肿瘤和间质CD8+T细胞数量与OS较差和无病生存期(DFS)较差相关(所有p<0.001)。
肿瘤中PD-L1的表达与OS较差有关,肿瘤或间质CD8+T细胞数量与OS较差和DFS较差有关。对于失去手术机会的患者,PD-L1免疫抑制治疗作为一种潜在治疗方法可能是未来研究的重点。